Prostate Cancer Clinical Trials

Showing 1161-1180 of 2,150 trials

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

NCT00779168

RATIONALE: White button mushroom extract may stop or delay the development of recurrent prostate cancer. PURPOSE: This phase I trial is studying the side effects and best dose of white button mushroom extract in treating patients with recurrent prostate cancer after local therapy.

Prostate Cancer

City of Hope Medical Center36 participantsStarted Jan 2009

Duarte, California, United States • South Pasadena, California, United States

COMPLETEDPhase 4

Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

NCT05304169

The purpose of this study is to evaluate the efficacy, quality of life and safety of switching from monthly (3.6 mg) or quarterly (10.8 mg) goserelin acetate (Zoladex®) to semiannual leuprorelin acetate 45 mg (Eligard® 45 mg) in prostate cancer patients with adequate hormonal castration level (plasma testosterone levels ≤50 ng/dL).

Prostate Cancer

Zodiac Produtos Farmaceuticos S.A.48 participantsStarted Nov 2017

Porto Alegre, Rio Grande do Sul, Brazil • Barretos, São Paulo, Brazil • Jaú, São Paulo, Brazil +3 more locations

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

Related Searches

Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

Cabazitaxel and Radiation For Patients With Prostate Cancer

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Study of Dasatinib, Androgen Deprivation Therapy and Radiation

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

Clinical Validation of the Prognostic Value of the PrTS on Prostate Cancer Patients

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Reduction of Prostate Biopsy Morbidity

SBRT for Organ Confined Prostate Cancer

Safety Study of MGA271 in Refractory Cancer

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Expanded Access [Ga-68] PSMA-11 PET Imaging